Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids. Carmustine (BCNU) given i.v. at a dose of 600 mg/m 2 was combined with etoposide and cyclophosphamide in 40 patients (BCV regimen) and with etoposide and melphalan in 25 patients (BEM regimen). Seventeen of 65 patients (26%) had one episode of NIPCs. The median time to NIPCs was 90 days (52-289). Factors that increased the risk of developing NIPCs on multivariate analysis were female sex (P Ͻ 0.001) and BCV regimen (P Ͻ 0.05). All patients with NIPCs received prednisone at a dose of 1 mg/kg body weight for 10 days then tapered by 5 mg every two days; complete response to steroids was achieved in 15 of 17 patients; one unresponsive patient died of interstitial pneumonia. BCNU given at the dose of 600 mg/m 2 is well tolerated when associated with melphalan and etoposide. In females and in patients receiving BCNU with cyclophosphamide, a BCNU dose reduction may be advisable. Bone Marrow Transplantation (2000) 25, 309-313. Keywords: carmustine; pulmonary toxicity; autologous peripheral blood progenitor cell transplantation There is evidence that several agents used in the preparative regimens for both autologous and allogeneic bone marrow transplantation may induce lung injury without evidence of infection. Agents that have been implicated include carmustine (BCNU), busulphan, cyclophosphamide (CY), and total body irradiation.
There is evidence that several agents used in the preparative regimens for both autologous and allogeneic bone marrow transplantation may induce lung injury without evidence of infection. Agents that have been implicated include carmustine (BCNU), busulphan, cyclophosphamide (CY), and total body irradiation. 1 BCNU causes toxic lung reactions characterized by chronic interstitial fibrosis, cough, dyspnea and decrease in lung diffusing capacity; toxicity related to the use of BCNU is suspected to be caused by damage to the glutathione system. 2 BCNU has been included in highdose conditioning regimens for gliomas, breast cancer, Hodgkin's disease, non-Hodgkin's lymphomas, multiple myeloma. Toxic pulmonary reactions have been recognized in as many as 16-64% of patients; [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] onset generally occurs within 1 year of starting BCNU. Events occurring up to 17 years later have been reported. 14 The drug seems to cause pulmonary damage in a dose-related manner: 5, 10, 11 Phillips et al 6 reported a 9.5% incidence of fatal pulmonary toxicity in patients receiving BCNU doses as high as 1.200 mg/m 2 as a single agent; another report suggests no pulmonary toxicity at doses of less than 1000 mg/m 2 . 7 The threshold dose for BCNU toxicity is still controversial: lung toxicity may occur at 600 mg/m 2 when the drug is associated with other toxic agents like CY. 1, 15 This report deals with patients with hematological malignancies who received a carmustine-based preparative regimen; the drug was combined with cyclophosphamide and etoposide or with etoposide and melphalan and both regimens were followed by autologous peripheral blood progenitor cell (PBPC) transplantation. The aim of this retrospective analysis was to characterize the incidence of pulmonary toxicity in patients treated with two diverse carmustine-containing regimens, and also to determine predictive risk factors and response to steroid therapy.
Methods
The medical records of 65 patients undergoing autologous PBSC transplantation who had received a BCNU-containing preparative regimen were reviewed to assess the incidence of pulmonary complications occurring within 12 months from transplant and the risk factors for their development; response to steroid therapy was also evaluated. All data concerning the total dose of cyclophosphamide, bleomycine, history of radiation and mediastinal involvement, history of smoking, previous history of pneumonitis or other lung diseases were taken into account. Episodes of pulmonary toxicity occurring after the first 12 months were excluded. The study includes only patients with normal pulmonary function tests before transplant.
All pulmonary complications occurring within 12 months from transplant were recorded. They were classified as fol-lows: (1) minor complications: reduction by 20% of singlebreath carbon monoxide diffusing capacity (DLCO) without any other sign or symptoms; (2) major complications: reduction of the above-reported parameter with symptoms (cough, dyspnea, fever) and signs (tachypnea, tachycardia, crackles or wheezes on auscultation) associated or not associated with evidence of interstitial pneumonia on chest radiograph. Patients with minor or major complications without evidence of bacterial, viral or fungal infection despite extensive examination, were classified as having non-infective pulmonary complication (NIPC). Patients with NIPC received prednisone therapy orally at a dose of 1 mg/kg body weight for 10 days, then tapered by 5 mg every other day.
Preparative regimens
Patients received as conditioning regimen a combination of BCNU, etoposide, melphalan (BEM regimen) or BCNU, etoposide and cyclophosphamide (BVC regimen). The BEM regimen was given to 25 patients with multiple myeloma: it consisted of BCNU 600 mg/m 
Pulmonary function evaluation
Pulmonary function tests including spirometry and DLCO were performed before transplant in all patients. Patients were routinely followed monthly for 3 months and every 3 months thereafter. Patients with cough, fever, or chest tightness underwent post-transplant chest radiography and additional spirometry with DLCO. In some cases bronchoalveolar lavage (BAL) and trans-bronchial biopsy were performed; patients were selected for these procedures if they had major complications and gave their informed consent.
Statistics
Descriptive statistics have been calculated for all variables. Data on patient ages, sex, diagnosis, previous radiation treatment, history of smoking, mediastinal involvement, mediastinal field radiotherapy, pretransplant pulmonary complications, previous treatment with bleomycine, and conditioning regimen were analyzed to assess by a Cox model their predictive value for the occurrence of noninfective pulmonary complications: all the potential risk factors (P Ͻ 0.1) identified on univariate analysis were included in a multivariate Cox model. In the event of collinearity, choice of variable was based on clinical importance.
Kaplan-Meier estimates of pulmonary complications were computed and curves drawn for selected variables. A P value of 0.05 was considered statistically significant. Stata 5.0 (College Station, TX, USA) was used for computation.
Results

Patients' characteristics
Sixty-five patients undergoing autologous PBPC transplantation who had received a BCNU-containing preparative regimen were identified. Their main characteristics are shown in Table 1 . The median age was 40 years (range 13-61). Thirty-three were male and 32 female. Thirteen had a history of smoking. Previous pulmonary complications were recorded in two cases; both had bacterial pneumonia. Eighteen patients with HD had received bleomycine together with adriamycin, vincristine and dacarbazine (ABVD scheme). Twenty-three patients had had mediastinal involvement and 12 of these had received radiotherapy to the mediastinum with a median dose of 35 Gy (range 25-40 Gy). Twenty-five patients with MM received the BEM regimen, while 40 patients with advanced HD or NHL had the BCV regimen (Table 2 ). PBPC were mobilized by cyclophosphamide given at a dose of 4000 mg/m 2 followed by G-CSF (5 g/kg/day) in all cases. One or two leukapher- Median time of pulmonary complication and 90 (52-289) range (days) NHL = non-Hodgkin's lymphoma; HD = Hodgkin's disease; MM = multiple myeloma; BEM = carmustine, etoposide, melphalan; BCV = carmustine, cyclosphosphamide, etoposide. /kg CD34-positive cells.
Pulmonary complications
Pulmonary complications occurring within 1 year from transplant occurred in 24 of 65 patients; seven had infection-related pulmonary complications, 17 non-infectious pulmonary complications (NIPCs) ( Table 1) . NIPCs were classified as major pulmonary complications in 11 patients; six patients only had a reduction of DLCO, classified as a minor complication. One NHL patient with major NIPCs died of acute respiratory distress on day +52 from transplant. The median time for pulmonary complication presentation was 90 days (range 52-289 ). Broncho-alveolar lavage was performed in seven cases; five underwent a transbronchial biopsy which showed evidence of interstitial pneumonia (two cases) and signs of lymphocytic alveolitis and septal fibrosis (three cases). The incidence of NIPCs given as event per person per year of observation was higher in patients receiving the BCV regimen ( Table 2 ). All patients with major or minor complications started steroids at the dosage of 1 mg/kg day for 10 days which were then tapered by 5 mg every other day. Complete resolution was achieved in eight cases within 3 weeks, with improvement in functional tests, signs and symptoms. Response to treatment was reached at a median of 8 weeks in seven patients. One unresponsive patient died of interstitial pneumonia. Another patient had only slight improvement; he is still receiving steroids at the small dose of 0.1 mg/kg of prednisone on day +900 from transplant.
Prognostic factors
Results from univariate and multivariate analysis are summarized in Table 3 . Age, sex, conditioning regimens and Bone Marrow Transplantation diagnosis appear to be significant prognostic factors on univariate analysis, while on multivariate analysis, conditioning regimen and sex are the only independent prognostic factors (Table 3 ) (Figure 1 ).
Discussion
Cytotoxic chemotherapy and radiotherapy given as preparation for autologous hemopoietic stem cell transplantation have been associated with the development of NIPC. 16 BCNU, increasingly used in several high-dose chemotherapy combinations, induces NIPC in as many as 15-42% of patients with HD, NHL or MM; 5,9,10,17 its lung toxicity seems to increase with the total dose given and the toxicity threshold is higher in patients receiving the drug as a single agent than in those receiving BCNU along with cyclophosphamide or other chemotherapeutic agents. [5] [6] [7] 12, 15 In the present study, 65 patients with hematological malignancies received BCNU at the dose of 600 mg/m 2 together with etoposide and cyclophosphamide (BCV) in 40 cases and with melphalan and etoposide (BEM) in 25 cases. The higher incidence of major NIPC observed in patients treated with BCV compared with those who received BEM (35% vs 12%) supports the hypothesis that CY may augment the detrimental effect of BCNU on the lungs; comparable results were observed in breast cancer patients receiving BCNU associated with CY and cisplatin. 3 In a dose toxicity study of 72 patients receiving a modified BEM regimen Ager et al 5 observed that BCNU given at the dose of 600 mg/m 2 to seven patients (five lymphomas, one ANLL, one MM), was associated with an unacceptable incidence of lung toxicity (42%); Rubio et al 4 reported idiopathic pneumonia in 28% of patients with relapsed HD receiving a BEM regimen, while in our study patients receiving BEM had minimal lung toxicity; they all had MM.
Diagnosis, previous chemotherapy and status at transplant may have a role in inducing NIPCs; in our study, however, multivariate analysis did not demonstrate the impact of diagnosis and previous chemotherapy in predicting NIPC (Table 3) .
Risk factors favoring NIPCs may be previous lung disease, a history of smoking, 18 previous treatment with bleomycine or chest radiotherapy. 19 In our study, however, none of these factors reached statistical significance (Table 3) . BCV conditioning regimen and female sex were the only risk factors for the development of NIPC on multivariate analysis. The increased toxicity noticed in females has been previously reported; there is, however, no explanation for this fact; 4,20 the use of oral contraceptive pills may perhaps be involved.
Lung injury induced by BCNU can be reversed by steroids which may reduce symptoms and improve DLCO. 18, 21, 22 Early reports, however, suggested no benefit. 23 Jones and co-workers 21 reported symptomatic improvement in 12 of 13 breast cancer patients treated with prednisone. Some authors advise immediate initiation of prednisone therapy to reduce need for long-term treatment and fatal outcome. 22 In our study, patients received prednisone promptly at the onset of symptoms or at least when a reduction of DLCO was noticed. This approach induced response in 16 of 17 patients (94%). Despite the good results observed in our study, the lack of a control group renders the conclusions tentative. In some reports late administration of steroids may explain the high incidence of fatal NIPC. 4, 5 Prophylactic use of steroids concurrent with BCNU to prevent pulmonary toxicity or progression of toxicity is still debatable: 6, 7, 24 its use should be tested in a randomised trial.
In our study the main NIPC risk factors were BCV combination and female sex. Patients receiving high-dose BCNU should have close follow-up with frequent DLCO determinations to allow prompt initiation of steroid therapy which may be of value in reducing need for long-term treatment and fatal complications; a reduction in BCNU dosage is probably advisable in females and in patients receiving BCNU along with cyclophosphamide where the incidence of NIPC was particularly high.
